PITPNM3 Antibody

1. CCL18 can increase the invasive ability of non-small cell lung cancer cells by binding to its receptor Nir1. PMID: 26756176
2. CCL18 enhances hepatocellular carcinoma (HCC) cell migration, invasion, and epithelial-mesenchymal transition (EMT) through the expression of PITPNM3 and the activation of the NF-kappaB signaling pathway. PMID: 26449829
3. Data indicate that PYK2 N-terminal domain interacting receptor 1 (Nir1) could induce epithelial-mesenchymal transition by stabilising Snail via the PI3K/Akt/GSK3beta/Snail signalling pathway through binding to CCL18. PMID: 24001613
4. Our observations of the PITPNM3 p.Q626H mutation carriers confirm that CORD5 is a disease not to mix with other retinal degenerations mapped to 17p13. PMID: 22405330
5. CCL18 derived from Tumor-associated macrophages (TAMs) lays a critical role in promoting breast cancer metastasis via its receptor, PITPNM3. PMID: 21481794
6. Thus, mutations in PITPNM3 do not appear to be a major cause of cone or cone-rod dystrophy. PMID: 20590364
7. Our finding on the first mutation in the human homologue of Drosophila rdgB indicates novel pathways and a potential important role of the PITPNM3 in mammalian phototransduction. PMID: 17377520
8. Mutation in the PYK2-binding domain of PITPNM3 causes autosomal dominant cone dystrophy (CORD5) in two Swedish families. PMID: 18188949

Show More

Hide All

HGNC: 21043

OMIM: 600977

KEGG: hsa:83394

STRING: 9606.ENSP00000262483

UniGene: Hs.183983